Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.33 |
| ▸ | ESRRG | P62508 | 3/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407329 | 0.85 | ESRRG (0.32) | APPESRRGHSD17B1HSD17B2ESR1 | |
| SCHEMBL6278264 | 0.85 | WRN (0.32) | APPESRRGHSD17B1HSD17B2ESR1 | |
| SCHEMBL6272796 | 0.82 | WRN (0.31) | ESRRG | |
| SCHEMBL6272802 | 0.81 | HSD17B1 (0.31) | APPHSD17B1HSD17B2 | |
| SCHEMBL6403483 | 0.74 | HSD17B2 (0.33) | APPHSD17B1HSD17B2 | |
| SCHEMBL6253453 | 0.69 | FDPS (0.36) | ESR2 | |
| SCHEMBL6752815 | 0.64 | ACP3 (0.43) | — | |
| SCHEMBL13044656 | 0.60 | IDO1 (0.42) | ESR1ESR2 | |
| SCHEMBL6402237 | 0.60 | LMNA (0.33) | — | |
| SCHEMBL6314562 | 0.60 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | APP 374/4885ESRRG 349/4885HSD17B1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.